AGLE News and Press, Aeglea BioTherapeutics Inc. From 04/12/22

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on nex...

Additional data from a phase 3 trial of Aeglea BioTherapuetics' (NASDAQ:AGLE) pegzilarginase for the rare inherited metabolic disorder Arginase 1 Deficiency (ARG1-D) sent shares surging 40% in after-hours trading. In a patient-level outcomes analysis, 11 patients (65%) receiving peg...

Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD PR Newswire AUSTIN, Texas , April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical...

Gainers: Aeglea BioTherapeutics (AGLE) +10%. Gossamer Bio (GOSS) +8%. Resources Connection (RGP) +7%. Conn's (CONN) +6%. Pixelworks (PXLW) +5%. Losers: Qorvo (QRVO) -7%. SoFi Technologies (SOFI) -5%. Deciphera Pharmaceuticals (DCPH) -5%. Oxford Lane Capital  (OXL...

Shares of Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) traded today at $12.80, eclipsing its 52-week high. Approximately 14.4 million shares have changed hands today, as compared to an average 30-day volume of 349,000 shares. Aeglea BioTherapeutics Inc is a clinical-stage biotechnology comp...

Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022 PR Newswire AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting PR Newswire AUSTIN, Texas , March 29, 2022 ...

Aeglea BioTherapeutics press release (NASDAQ:AGLE): FY GAAP EPS of -$1.00 beats by $0.02. Revenue of $18.73M beats by $1.33M. As of December 31, 2021, the company had available cash, cash equivalents, marketable securities and restricted cash of $95.0 million For further details see: Ae...

Aeglea BioTherapeutics (AGLE -6.5%) is trading lower for the third straight session after announcing that Sara Brownstein, a Class I director of its Board, informed the company on Wednesday that she would resign, effective Feb. 09. “The Company believes Ms. Brownstein’s resignat...